Search Results - Filipa Lynce
- Showing 1 - 18 results of 18
-
1
A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aro... by Tina Roy, Elizabeth Barrows, Candace Mainor, Julie Collins, Filipa Lynce, Claudine Isaacs, Paula R. Pohlmann
Published in Contemporary Clinical Trials Communications (2023-06-01)Get full text
Article -
2
-
3
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial trea... by Renee N Donahue, Jeffrey Schlom, Nicole J Toney, Claudine Isaacs, Filipa Lynce, Candace Mainor, Megan T Lynch
Published in Journal for ImmunoTherapy of Cancer (2025-04-01)Get full text
Article -
4
-
5
Oncotype DX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early Breast Cancer: A Retrospective Observational Study by Stefania Morganti, Rabia A. Khan, Luis C. Berrocal-Almanza, Miguel Miranda, Linlin Luo, Xiaoqing Xu, Ann H. Partridge, Filipa Lynce
Published in Oncology and Therapy (2025-04-01)Get full text
Article -
6
982 Immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC) by Geoffrey I Shapiro, Anita Mehta, Jennifer L Guerriero, Adam Nelson, Patrice A Lee, Madisson Oliwa, Filipa Lynce, Nabihah Tayob, Madeline G Townsend, Kelly F Zheng, Nicholas A Saccomano
Published in Journal for ImmunoTherapy of Cancer (2023-11-01)Article -
7
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer by Paolo Tarantino, Julieta Leone, Carlos T. Vallejo, Rachel A. Freedman, Adrienne G. Waks, Olga Martínez-Sáez, Ana Garrido-Castro, Filipa Lynce, Nabihah Tayob, Nancy U. Lin, Sara M. Tolaney, Jose P. Leone
Published in npj Breast Cancer (2024-04-01)Get full text
Article -
8
1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC by Geoffrey I Shapiro, Jessica Thaxton, Anita Mehta, Jennifer L Guerriero, Adam Nelson, Carlos Wagner Wanderley, Filipa Lynce, Madeline G Townsend, Kelly F Zheng, Daniel E Michaud, Kiran Kurmi, Shakchhi Joshi, Marcia Haigis
Published in Journal for ImmunoTherapy of Cancer (2023-11-01)Article -
9
D84. Pre-operative Lymphedema Risk Factors in Patients with Inflammatory Breast Cancer: Optimizing Patient Selection for LYMPHA by Colby J. Hyland, BA, Libby R. Copeland-Halperin, MD, David Xiang, BA, Goutam Gadiraju, BA, Jennifer R. Bellon, MD, Filipa Lynce, MD, Tanujit Dey, PhD, Sean J. Ryan, MA, MS, Faina Nakhlis, MD, Justin M. Broyles, MD
Published in Plastic and Reconstructive Surgery, Global Open (2023-04-01)Get full text
Article -
10
SP33. Optimizing Patient Selection for Lympha in Patients with Inflammatory Breast Cancer by Colby J. Hyland, AB, Libby R. Copeland-Halperin, MD, Goutam K. Gadiraju, BS, David Xiang, AB, Jennifer R. Bellon, MD, Filipa Lynce, MD, Tanujit Dey, PhD, Sean J. Ryan, MA, MS, Faina Nakhlis, MD, FACS, Justin M. Broyles, MD
Published in Plastic and Reconstructive Surgery, Global Open (2023-05-01)Get full text
Article -
11
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer by Ana C. Garrido-Castro, Meredith M. Regan, Samuel M. Niman, Faina Nakhlis, Claire Remolano, Jennifer M. Rosenbluth, Caroline Block, Laura E. Warren, Jennifer R. Bellon, Eren Yeh, Beth T. Harrison, Elizabeth Troll, Nancy U. Lin, Sara M. Tolaney, Beth Overmoyer, Filipa Lynce
Published in npj Breast Cancer (2023-06-01)Get full text
Article -
12
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer by Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A. Mittendorf, Tari A. King, Anna Weiss, Ann H. Partridge, Brittany L. Bychkovsky, Giuseppe Curigliano, Nabihah Tayob, Nancy U. Lin, Judy E. Garber, Sara M. Tolaney, Filipa Lynce
Published in npj Breast Cancer (2024-04-01)Get full text
Article -
13
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study by Kristina Fanucci, Eren D. Yeh, Ruichao Shi, Lei Qin, Camden P. Bay, Molly DiLullo, Ashka Patel, McKenna Moore, Zachary T. Herbert, Beth T. Harrison, Faina Nakhlis, Jennifer Bellon, Laura Warren, Jennifer L. Guerriero, Sara M. Tolaney, Meredith Regan, Beth Overmoyer, Steven Van Laere, Filipa Lynce
Published in Breast Cancer Research (2025-09-01)Get full text
Article -
14
885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab by Edward T Richardson, Geoffrey I Shapiro, Jennifer L Guerriero, Claudine Isaacs, Filipa Lynce, Madeline G Townsend, Kelly F Zheng, Paula R Pohlmann, Kenichi Shimada, Arielle Heeke, Xue Geng, Candace Mainor, Mei Wei, Julie M Collins, Lauren M Sloat, Jane Staunton, Stuart J Schnitt, Joan S Brugge, Hongkun Wang
Published in Journal for ImmunoTherapy of Cancer (2023-11-01)Article -
15
Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study by Ilana Schlam, Kelly A. Hirko, Daniela Shveid, Inas Abuali, Sarah Sewaralthahab, Faina Nakhils, Aditi Hazra, Csongor Lengyel, Sara Altuna, Sadaqat Hussain, Fahmi Seid, Sara Jamil, Andrew Odhiambo, Jose Pablo Leone, Otto Metzger, Jame Abraham, Enrique Soto-Perez-de-Celis, Wendy Y. Chen, Caroline Block, Susan Schumer, Jennifer R. Bellon, Carmine Valenza, Giuseppe Curigliano, Sara M. Tolaney, Filipa Lynce, Dario Trapani
Published in JCO Global Oncology (2024-12-01)Get full text
Article -
16
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study by Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M. Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M. Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs
Published in Nature Communications (2024-03-01)Get full text
Article -
17
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study by Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M. Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M. Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs
Published in Nature Communications (2024-05-01)Get full text
Article -
18
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer by Filipa Lynce, Laura E. Stevens, Zheqi Li, Jane E. Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M. Force, Tufia C. Haddad, Naoto Ueno, Vered Stearns, Antonio C. Wolff, Amy S. Clark, Jennifer R. Bellon, Edward T. Richardson, Justin M. Balko, Ian E. Krop, Eric P. Winer, Paulina Lange, E. Shelley Hwang, Tari A. King, Sara M. Tolaney, Alastair Thompson, Gaorav P. Gupta, Elizabeth A. Mittendorf, Meredith M. Regan, Beth Overmoyer, Kornelia Polyak
Published in Breast Cancer Research (2024-01-01)Get full text
Article